Search PubMed⌕ Search

Biomedical subjects

J M Wit

Publications and source records attributed to J M Wit.

At least 199 records · Page 11Linked to original sources
PubMed1986

Effect of LHRH treatment on testicular descent and hormonal response in cryptorchidism.

In a double-blind placebo-controlled study in 49 boys with cryptorchidism the effect of intranasal synthetic LHRH was studied. After 8 weeks improvement in testicular location was found in 13 testes (37%), but this improvement was considered sufficient of only six testes. Placebo resulted in an improved location in 18% of the testes. The mean change in testicular position (expressed in cm) after LHRH therapy was slightly greater than after placebo but only in the squatting position did this difference reach significance. Aggressive behaviour was reported in 23% of the children treated with LHRH. A second LHRH course did not result in significant improvement in any of the patients. At follow-up reascent was frequently seen. The final results in unilateral cryptorchidism are poorer than those in bilateral cryptorchidism. LHRH therapy leads to higher plasma LH levels and a lower FSH in response to an intravenous LHRH test. In 15 boys plasma testosterone levels rose above 0.4 nmol/l. We conclude that intranasal LHRH application has a limited value for the treatment of cryptorchidism but may be suitable as a diagnostic test.

Child↗
PubMed1986

Growth response to human growth hormone treatment in children with partial and total growth hormone deficiency.

The growth response during the first and second years of human growth hormone (hGH) treatment was studied in 14 prepubertal children with so-called "partial" GH deficiency (peak GH between 8 and 15 mU/l) and compared to 28 prepubertal children with "total" GH deficiency (peak GH less than 8 mU/l). There was no difference in growth acceleration between children with partial and total GH deficiency, when initial covariables were taken into account. In a stepwise multiple regression analysis initial stature, pre-treatment growth velocity and skinfold thickness were shown to be most related to growth response, but after exclusion of 3 children with a genetic form of total GH deficiency and partial TSH deficiency this relationship was lost. GH levels during provocation tests and auxological criteria have a poor predictive value for growth response to hGH therapy.

Anthropometry↗
PubMed1986

[Current developments in the treatment of growth delay using growth hormone].

In this paper five new developments in the field of growth hormone (GH) deficiency and its treatment are discussed. Firstly, the changing concepts on the definition of GH deficiency are described. The main criteria for GH deficiency are a low growth velocity and a decreased GH secretion, but for none of these parameters clear limits can be drawn. Secondly, the results of GH therapy in children with normal GH responses to provocative stimuli are reviewed. Growth velocity does increase in many of these children, but it is not yet known if the final height will increase. Thirdly, new modes of administration are discussed, as well as the GH dosage and the frequency of injections. Daily subcutaneous administration seems to be superior in terms of growth promoting effect. The fourth new development, the production of biosynthetic GH, is certainly the most important. This will soon lead to an unlimited supply of GH with great consequences for the type of patients that will be treated and for the dosage that will be given. Finally, the pharmacological agents which can stimulate the GH secretion are described, particularly growth hormone releasing factor (GRF). The therapeutical use of GRF is still in an experimental phase. In the present circumstances it is very important that GH therapy be given in a well standardized way. For the time being concentration of patients into the centres of pediatric endocrinology will remain advantageous.

Animals↗
PubMed1985

Neonatal thyrotoxicosis treated with exchange transfusion and Lugol's iodine.

An infant with neonatal thyrotoxicosis was born to a mother who had become euthyroid after subtotal thyroidectomy for Graves' disease. Exchange transfusion resulted in a 50% decrease of serum thyroxine levels and thyroid stimulating immunoglobulins. After 10 days mild thyrotoxic signs reappeared with high serum thyroxine levels, which were treated successfully with Lugol's iodine for 4 weeks. TSI was undetectable at 7 weeks of age. TSI was present in breast milk.

Adult↗
PubMed1985

Cerebral gigantism (Sotos syndrome). Compiled data of 22 cases. Analysis of clinical features, growth and plasma somatomedin.

An in depth study on growth, bone age, cranial CT scans and plasma somatomedin activity (SM-act) was made of 22 children with Sotos syndrome. In addition to the known characteristics of the syndrome, thin and brittle nails were found in three adolescent patients. The mean body stature, expressed as standard deviation score, increased from 2.2-2.8 in the 1st year of life, followed by a fall to 2.0 in the 2nd year. Thereafter the SDS increased slowly to values of 3.0 at 10 years of age. At least two subjects have reached an exceptionally tall final stature. After the age of 2 years, delta SDS/year remained very stable (-0.1-0.2), concurring with growth velocities in the upper normal range. Bone age was advanced in all patients. Cranial CT scans showed ventricular widening, mid-line cava and Sylvian anomalies in nine, six, and three patients respectively. SM-act dropped from high or normal values in the 1st year, to below normal from 1-5 years, and returned thereafter to the lower half of normal or below the normal range.

Abnormalities, Multiple↗
PubMed1984

Plasma somatomedin activity and urinary hydroxyproline excretion during administration of human growth hormone in children with short stature. Short-term effects.

15 prepubertal children with short stature and varying peak growth hormone (GH) levels were given daily injections of increasing doses of human growth hormone (hGH) for consecutive periods of 7 days. Somatomedin activity (SM-act) and total urinary hydroxyproline excretion (THP) were determined in each period. In patients with a varying degree of GH deficiency, but without non-pituitary dependent abnormalities, there was a high correlation between basal SM-act and height velocity. Patients with catch-up growth had an unproportionally low SM-act and the Prader-Willi and transient Cushing patients had an unproportionally high one. All patients showed increases of SM-act and THP on hGH administration, but there was considerable variation of the shape of the curve and of the amplitude of the response. 3 1/2 days after the last injection, SM-act was back to basal level. There was a good correlation between weight-for-height and SM-act during the first two hGH doses, which fits the hypothesis of GH and insulin synergism on SM generation.

Adolescent↗
PubMed1984

Plasma somatomedin activity and urinary hydroxyproline excretion during administration of human growth hormone in children with short stature. Long-term effects and relation with short-term changes.

Growth velocity, somatomedin activity (SM-act) and total urinary hydroxyproline excretion (THP) were studied in 9 prepubertal short children on long-term human growth hormone (hGH) therapy, and compared to the short-term responses to hGH, described in the accompanying paper. Positive correlations were found between the short-term increases of either SM-act or THP and growth acceleration, but these were too weak to be used as a predictor. On a schedule of biweekly injections, pre-injection SM-act values were only slightly higher than pre-treatment values, but post-injection values were considerably higher and similar to the values obtained with comparable hGH doses in the short-term study. There was an excellent relationship of the increment of SM-act during chronic therapy over untreated values and the increases of growth velocity. During the first year on hGH therapy the mean SM-act, mean THP and growth acceleration showed strong correlations.

Adolescent↗
PubMed1984

Reference curves for biceps, triceps, subscapular and suprailiac skinfolds in Dutch children from 7-14 years.

Box-Cox transformation of skinfold measurement data from the Nymegen Growth Study produced reference curves for biceps, triceps, subscapular and suprailiac skinfolds and their sums with an acceptable Gaussian distribution at all ages. The population sample, resulting in 1850 skinfold measurements for boys and 2250 for girls by a single observer, was obtained by random selection and can be considered as representative for The Netherlands. The Gaussian distribution after Box-Cox transformation allows the use of standard deviation scores. Seven percentile curves are presented for boys and girls of 7-14 years of age.

Adolescent↗
PubMed1983

Behaviour therapy of obese children and results 21 months after treatment.

Two groups of pre-pubescent obese children were given modified behaviour therapy. A shaping procedure was used to bring about changes in quantity and quality of food eaten, physical activities, and eating behaviour. In addition, attempts were made to get the children to distinguish better between hunger and satiation and to improve the interactions between children and parents. The children were trained to effect desired behavioural changes themselves on the basis of their own observations. Four of the 11 children displayed a substantial weight reduction which was maintained in follow-up. In the case of the other children it appeared that psychopathological and constitutional factors prevented them from making use of the strategy offered.

Adolescent↗